[EN] HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE [FR] MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE DE TYPE DIAMINE URÉE SPIROCYCLIQUE SUBSTITUÉE PAR UN GROUPE HÉTÉROARYLE
[EN] ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS HETEROCYCLIQUES A BASE D'UREE A SUBSTITUTION ARYLE DE L'HYDROLASE DES AMIDES D'ACIDES GRAS (FAAH)
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2010141809A1
公开(公告)日:2010-12-09
Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase
作者:John M. Keith、William Jones、Joan M. Pierce、Mark Seierstad、James A. Palmer、Michael Webb、Mark Karbarz、Brian P. Scott、Sandy J. Wilson、Lin Luo、Michelle Wennerholm、Leon Chang、Michele Rizzolio、Raymond Rynberg、Sandra Chaplan、J. Guy Breitenbucher
DOI:10.1016/j.bmcl.2020.127463
日期:2020.10
A series of mechanism-based heteroaryl urea fatty acid amide hydrolase (FAAH) inhibitors with fused bicyclicdiamine cores is described. In contrast to compounds built around a piperazine core, most of the fused bicyclicdiamine bearing analogs prepared exhibited greater potency against rFAAH than the human enzyme. Several compounds equipotent against both species were identified and profiled in vivo
HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE
申请人:Breitenbucher J. Guy
公开号:US20120083476A1
公开(公告)日:2012-04-05
Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
申请人:Breitenbucher J. Guy
公开号:US08901111B2
公开(公告)日:2014-12-02
Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase
作者:John M. Keith、William M. Jones、Joan M. Pierce、Mark Seierstad、James A. Palmer、Michael Webb、Mark J. Karbarz、Brian P. Scott、Sandy J. Wilson、Lin Luo、Michelle L. Wennerholm、Leon Chang、Sean M. Brown、Michele Rizzolio、Raymond Rynberg、Sandra R. Chaplan、J. Guy Breitenbucher
DOI:10.1016/j.bmcl.2013.12.113
日期:2014.2
A series of mechanism based heteroaryl urea fatty acid amide hydrolase (FAAH) inhibitors with spirocyclic diamine cores is described. A potent member of this class, (37), was found to inhibit FAAH centrally, elevate the brain levels of three fatty acid ethanolamides [FAAs: anandamide (AEA), oleoyl ethanolamide (OEA) and palmitoyl ethanolamide (PEA)], and was moderately efficacious in a rat model of neuropathic pain. (C) 2014 Elsevier Ltd. All rights reserved.